These differences in survival outcomes with trastuzumab or immunotherapy were limited to CCNE1-amplified gastric adenocarcinoma, as we did not find any significant survival differences in CCNE1-amplified EA or EJC after trastuzumab or immunotherapy, although there was a slight trend toward improved survival after immunotherapy in CCNE1-amplified EJC (Supplementary Fig. S7B, S7C, S7E, and S7F). This evidence concerns the gene CCNE1 and gastric adenocarcinoma.